A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502646-27-00

Acronym

MK-2140-003

Enrollment

Registered

2023-04-27

Start date

2022-06-24

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Brief summary

Percentage of Participants with Dose-limiting Toxicities (DLTs), Percentage of Participants with Adverse Events (AEs), Percentage of Participants who Discontinue Study Treatment due to AE, Overall Survival (OS), Progression-Free Survival (PFS)

Detailed description

Objective Response Rate (ORR), Duration of Response (DOR)

Interventions

DRUGMabThera 500 mg concentrate for solution for infusion

DRUGZilovertamab vedotin

DRUGOXALIPLATIN

DRUGMabThera 100 mg concentrate for solution for infusion

DRUGBENDAMUSTINE HYDROCHLORIDE

DRUGRuxience 500 mg concentrate for solution for infusion

DRUGRuxience 100 mg concentrate for solution for infusion

DRUGGEMCITABINE

DRUG-

DRUGTruxima 500 mg concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of Participants with Dose-limiting Toxicities (DLTs), Percentage of Participants with Adverse Events (AEs), Percentage of Participants who Discontinue Study Treatment due to AE, Overall Survival (OS), Progression-Free Survival (PFS)	—

Secondary

Measure	Time frame
Objective Response Rate (ORR), Duration of Response (DOR)	—

Countries

France, Greece, Italy, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026